NIKKEI 225
38,189.54 -216.12 (-0.56%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.13 -0.80 (-0.98%) GOLD FUTURES
2,297.70 -5.20 (-0.23%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
47,964.67 -3,149.35 (-6.16%)
Waters Corporation (0LTI.L)
| Previous close | 310.36 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,075 |
| Market cap | 215.883M |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | 0.27 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns
Waters Corporation (NYSE:WAT) today introduced new GTxResolve Premier Size Exclusion Chromatography (SEC) 1000Å 3-micron (3 µm) Columns. Waters has implemented a unique combination of novel packing materials and MaxPeak™ Premier High-Performance Surface (HPS) technology into the columns to help scientists accelerate the development of gene-based therapeutics, including cell & gene, mRNA and LNPs.
- PR Newswire
Waters Corporation Schedules First Quarter 2024 Earnings Conference Call
Waters Corporation (NYSE:WAT) will hold its Q1 2024 financial results conference call live on Tuesday, May 7th, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 4th, 2024, at midnight Eastern Time.
- PR Newswire
Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors
Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories. The new HPLC system combines advanced bio-separation technology and built-in instrument intelligence features. It is designed to help biopharma QC analysts boost efficiency and eliminate up to 40% of common errors, saving time lost by investigating the source of fa
